All In Biotech

Drug Trial Radar · NCT01762514

A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens

A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday

Last checked: Nov 20, 2026Latest source record: Jul 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

360

Planned (sponsor's estimate)

Start

Jan 2013

Primary completion

Jun 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dalian Merro Pharmaceutical Co. Ltd
First posted
Jan 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE * Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. * Radiotherapy may cause adverse effect such as xerostomia and mucositis. * Amifostine has the ability of protecting the normal tissue but also has some side effects. PURPOSE * This phase II trial is to study the protecting effect and safety of different Amifostine regimens in patients with nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Neoplasms
  • Salivary Gland Diseases
  • Bone Marrow Diseases
  • Mucositis

Interventions

  • Amifostine every-other-day regimenDrug

    Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy

  • Amifostine everyday regimenDrug

    Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect on improving myelosuppressionTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy
  2. Effect on improving xerostomiaTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy
  3. Effect on improving mucositisTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Main Guangzhou Hospital of the Guangzhou Military Region

    Guangzhou, Guangdong, China · Suspended

  • Department of Radiation Oncology, Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Cancer Hospital Of Guangzhou Medical Collage

    Guangzhou, Guangdong, China · Suspended

  • Guangdong Provincial Hospital Of Chinese Medicine

    Guangzhou, Guangdong, China · Suspended

  • The First Affiliated Hospital Of Guangzhou Medical Collage

    Guangzhou, Guangdong, China · Recruiting

  • The Second Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Suspended

  • Guangdong Second People's Hospital

    Guangzhou, Guangdong, China · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.